Abstract 12463: Awareness and Perceptions Towards Inflammatory Risk in Atherosclerotic Cardiovascular Disease: A Multinational Survey Amongst Cardiologists

Circulation, vol. 148

Abstract

Background: In patients (pts.) with atherosclerotic cardiovascular disease and chronic kidney disease (ASCVD+CKD), systemic inflammation (SI) contributes to high cardiovascular (CV) risk. Awareness and perception of SI and use of high sensitivity C-reactive protein (hsCRP) amongst cardiologists is less understood. Aims FLAME-ASCVD survey assessed the level of awareness and perceptions of cardiologists towards the role of SI (primary objective) and hsCRP as a biomarker in pts. with ASCVD+CKD. Methods: This was a non-interventional, cross-sectional, global online survey-based study that collected data from interventional (IC) and/or general cardiologists (GC), treating ≥15 ASCVD+CKD pts./month and practiced for ≥3 years. Survey used an online questionnaire, across 10 countries (Australia, Brazil, China, France, Germany, India, Italy, Japan, Saudi Arabia, UK) during Mar-May 2023. Data were analysed using descriptive statistics. Results: Of the 1755 who responded to the survey invitation, 602 eligible cardiologists (IC=247, GC=355) completed the questionnaire (~60/country). Overall, CV risk factors discussed with pts. were hypertension (88%), hyperlipidaemia (82%), hyperglycaemia (78%), and SI ranked tenth at 43%. Overall, 72% agreed that SI was a risk factor for ASCVD, 64% as one of the drivers for CV events and 73% agreed that SI contributed to risk of recurrent CV events. Overall, 64% (n=386) acknowledged intent to test for SI in management, and 41% of these, stated that results influenced decision to initiate anti-inflammatory treatment. 49% of those not measuring for SI (n=216), stated lack of medication for SI as a reason. Overall, 47% used hsCRP as a test for SI and 45% stated the need for guidelines as one of the factors to establish testing in practice. Conclusion: In this survey, SI was perceived as a CV risk factor, but not to the same level as traditional CV risk factors. There is a need for better understanding of SI and hsCRP testing in patients with ASCVD+CKD.

Authors 8

1. Nikolaus Marx Aachen Univ Hosp Aachen

   Universitätsklinikum Aachen

   Affiliation as printed

   Univ Hosp Aachen, Aachen, Germany

   Nikolaus Marx Univ Hosp Aachen, Aachen, Germany

2. Issei Komuro

   The University of Tokyo · International University of Health and Welfare

   Affiliation as printed

   The Univ of Tokyo / International Univ of Health and Welfare, Tokyo, Japan

   Issei Komuro The Univ of Tokyo / International Univ of Health and Welfare, Tokyo, Japan

3. Amir Abbas Mohseni Zonoozi

   Novo Nordisk (Denmark)

   Affiliation as printed

   Novo Nordisk, Copenhagen, Denmark

   Amir A Mohseni Zonoozi Novo Nordisk, Copenhagen, Denmark

4. Preethy Prasad

   Novo Nordisk (Denmark)

   Affiliation as printed

   Novo Nordisk, Copenhagen, Denmark

   Preethy Prasad Novo Nordisk, Copenhagen, Denmark

5. Juying Qian

   Zhongshan Hospital

   Affiliation as printed

   Zhongshan Hosp, Shanghai, China

   Juying Qian Zhongshan Hosp, Shanghai, China

6. Jose F Saraiva

   Pontifícia Universidade Católica de Campinas

   Affiliation as printed

   Pontifical Catholic Univ of Campinas, Campinas, Sao Paulo, Brazil

   Jose F Saraiva Pontifical Catholic Univ of Campinas, Campinas, Sao Paulo, Brazil

7. Abhijit Shete

   Novo Nordisk (Switzerland)

   Affiliation as printed

   Novo Nordisk Health Care AG, Zurich, Switzerland

   Abhijit V Shete Novo Nordisk Health Care AG, Zurich, Switzerland

8. Alberico Luigi Catapano

   University of Milan

   Affiliation as printed

   Univ of Milan, Milano, Italy

   Alberico L Catapano Univ of Milan, Milano, Italy